Русский

Pharmaceutical Industry Information Portal

HomeNews

News

Manufacturers News

The Medsintez Plant has launched a full-cycle production of hypoglycemic drugs for treating type II diabetes mellitus

Techno -
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.
Manufacturers News

Pharmstandard has reached full capacity for manufacturing Plasma-Derived Coagulation Factor VIII for Haemophilia A treatment

Techno -
The product was developed as part of the state strategy for increasing the population's life expectancy and quality of life and improving medicine availability.
Manufacturers News

PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide

Techno -
The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.
Manufacturers News

GEROPHARM brings back Ozempic® with a new name: Semavic®

Techno -
To expand on the news about GEROPHARM's release of Semavic®, the company has introduced Semavic® as a domestic analogue to Ozempic®, responding to the cessation of Ozempic® imports from Denmark to Russia.
Expert Articles

GMP-inspections of veterinary manufacturers in the fourth quarter of 2023

Techno -
This review provides information on the inspection of manufacturers of veterinary medicines for compliance with the requirements of the Good Manufacturing Practice (GMP) which is carried out by specialists of the Federal State Budgetary Institution "The All-Russian State Center for Quality and Standardization of Veterinary Drugs and Feed" (FSBI "VGNKI").
Manufacturers News

The Ministry of Health of Russia authorizes a Russian anti-melanoma originator

Techno -
The Ministry of Health of the Russian Federation has authorized a Russian originator drug for the treatment of unresectable or metastatic melanoma. The product was developed by BIOCAD, a biotechnology company; it is a fixed dose combination of two monoclonal antibodies, nurulimab and prolgolimab.
123...110Page 2 of 110
spot_img

Expert Articles

spot_img

Information Internet project PharmProm.Net dedicated to the pharmaceutical industry in the world. It contains a contact base of organizations, enterprises, companies associated with the pharmaceutical market. The editorial staff of the PharmProm.Net portal offers cooperation in the field of information promotion and advertising in the pharmaceutical market.

Read our Russian-language online magazine

Categories